EMA clears Oryzon to launch HOPE-2 Phase II vafidemstat trial in Phelan-McDermid syndrome
Bitget2026/09/28 06:26- EMA cleared Oryzon Genomics to start the Phase IIa HOPE-2 trial of vafidemstat in Phelan-McDermid syndrome.
- Open-label, single-center study targets 12 adults in Spain, with 12 weeks of dosing and an option to extend to 24 weeks.
- Trial is partly funded through Oryzon’s VANDAM project under the EU-backed Med4Cure IPCEI health program.
- Spain’s Ministry of Science, Innovation and Universities, CDTI, and the EU’s NextGenerationEU are providing the public funding.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The EU questions why a certain exchange continues to operate after being asked to exit
How Strategy keeps STRC near $100 while MSTR stock swings
WTI Crude Oil Drops Over 1.00% Today, Currently at $88.55 per Barrel
Summary of the Bank of Japan's September meeting opinions: Majority of members advocate for continued rate hikes, some call for acceleration.
The summary of the Bank of Japan's September meeting opinions shows that some policymakers believe it is necessary to accelerate interest rate hikes or bring rates closer to the central bank's "target" as soon as possible, increasing the likelihood of further rate hikes.
Crypto prices
More
